CALOSYN PHARMA, INC.

Shreveport, LA · Founded 2007 · Biotech · Private

CAL-05CR, a sustained-release injectable therapeutic for osteoarthritis

Claim this profile

Follows are private to you and power your alerts

Updated · calosyn.com

Sector
Biotech
Headquarters
Shreveport, LA
Founded
2007
Latest Form D
$750K, Mar 2024
Total capital
$1.5M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$1.5M
3 Form D · last Mar 2024
32 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
5 pending · first 2025
Rank in peer group#481 of 1449

Capital timeline

20092011201320152017201920212023FEDERAL ↑EQUITY ↓Cumulative $1.5M1st Form D$400K2nd Form D$310K3rd Form D$750K
2009201320172021FEDERAL ↑EQUITY ↓Cumulative $1.5M2nd Form D$310K3rd Form D$750K

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$750K
  • Private capital raisedForm D · SEC · 2nd filing$310K
  • Private capital raisedForm D · SEC · 1st filing$400K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#481 · top 33%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • David WaddellDirectorNamed in SEC Form D filings
  • Joseph F. LovettDirectorNamed in SEC Form D filings
  • Martin BeckerExecutive Officer, DirectorNamed in SEC Form D filings
  • Mike ShermanDirectorNamed in SEC Form D filings
  • Richard R. BabbExecutive Officer, DirectorNamed in SEC Form D filings
  • Ross BarrettDirectorNamed in SEC Form D filings
Show all 8 people
  • Stephen SnowdyDirectorNamed in SEC Form D filings
  • William R. GrimesExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 6
  • PendingTherapeutics And Method For Treating OsteoarthritisUSPTOApplication 19325004
  • GrantedTherapeutics And Method For Treating OsteoarthritisUSPTOUS 12,433,899
  • PendingTherapeutics And Method For Treating OsteoarthritisUSPTOApplication 18681818
Show all 6 patent records
  • Therapeutics And Method For Treating OsteoarthritisJun 18, 2026 · Application 19325004Pending
  • Therapeutics And Method For Treating OsteoarthritisOct 7, 2025 · US 12,433,899Granted
  • Therapeutics And Method For Treating OsteoarthritisMay 1, 2025 · Application 18681818Pending
  • Methods for Treating OsteoarthritisSep 11, 2014 · Application 14022727Pending
  • Therapeutics And Methods For Treating OsteoarthritisApplication PCTUS2025014839Pending
  • Therapeutics And Method For Treating OsteoarthritisApplication PCTUS2022039755Pending
  • Amaryllis Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • Enkefalos Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
  • Accuitis Inc.Similar federal contract value in Biotech · null in contracts
  • Hepanova, Inc.Similar federal contract value in Biotech · null in contracts
  • Telos Biotech Inc.Similar federal contract value in Biotech · null in contracts
  • Koniku Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .